Chronic Lymphocytic Leukemia (CLL) Global Market Report 2023: Featuring BMS, Autolus Therapeutics & Sian Wuhan Medical Technology

Rhea-AI Summary

The latest report on Chronic Lymphocytic Leukemia (CLL) market forecasts a robust pipeline of cell therapies, particularly CAR-T therapies, which are projected to capture significant market share by 2031. The report estimates the CLL cell therapy market will reach $2 billion in annual sales across major pharmaceutical markets, with overall CLL market sales peaking at $20.8 billion. The analysis covers the clinical landscape, unmet needs, and future players within the market, emphasizing a shift towards cell therapies for high-risk patients. The report spans 15 major markets, providing insights into disease epidemiology and forecast methodologies.

Positive

• Projected CLL cell therapy market to reach $2 billion by 2031.
• Overall CLL market sales expected to peak at $20.8 billion.
• Significant presence of CAR-T therapies in the pipeline indicates growth potential.

Negative

• No approved CAR-T therapies in CLL due to manufacturing and clinical challenges.
• High safety profile expectations may limit therapy uptake.

DUBLIN, Feb. 17, 2023 /PRNewswire/ -- The "Chronic Lymphocytic Leukemia (CLL) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031" drug pipelines has been added to  ResearchAndMarkets.com's offering.

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late- clinical stage pipeline products, with a launch date assessment by market for chronic lymphocytic leukemia (CLL).

This report also contains a sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 major markets (15MM). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the publisher's World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of CLL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology. Additionally, the report evaluates indication-specific unmet needs and competitive assessments and identifies key future players in the cell therapy market.

CLL shows a promising and highly active cell therapy clinical pipeline .Cell therapy, consisting primarily of chimeric antigen receptor T-cell (CAR-T) therapies, constitutes a large proportion of the CLL pipeline, with approximately 20% of all agents in the clinical pipeline for CLL being cell therapies, making it the second most popular pipeline modality behind small molecules.

There are no approved CAR-T therapies in CLL due to manufacturing and clinical challenges. CLL is a relatively low-grade cancer type with effective and tolerable available treatment options, therefore the threshold for acceptable safety profiles for cell therapies is high. Moreover, the timing of receiving CAR-T is open to discussion, as end-stage patients stand to benefit from CAR-T but may not be fit enough to undergo the procedure

The publisher's PBF projects the CLL cell therapy market across the 8MM to reach $2 billion in annual sales in 2031, while across the 15MM, overall CLL market sales are projected to reach a peak of $20.8 billion.

Cell therapy is a promising modality for treating CLL and can provide the most value by demonstrating long-term disease control in high-risk and young patients. The cell therapy landscape in CLL is expected to change dramatically over the forecast period and may become the standard of care for relapsed/refractory patients and/or those with high-risk progressive disease if shown to be effective for long-term disease control.

Key Highlights

• Forecast includes 8 countries
• Forecast covers 2021-2031
• Seven markets are extrapolated, obtaining a 15-market value for all CLL therapeutics

Scope

• This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy

OBTAIN CELL THERAPY SALES FORECASTS ACROSS MULTIPLE REGIONS
GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as:

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?

Key Topics Covered:

1. Preface
1.1. Contents
1.2. Report Scope

2. Executive Summary

3. Disease Overview

4. Pipeline Drugs Overview
4.1. Pipeline Analysis
4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers
5.2. 10-Year Market Analysis with Drivers and Barriers - 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment
8.1. Competitive Analysis by Class of Therapy

9. Future Players and Catalyst
9.1. Future Players Based on Pipeline Strength

10. Appendix
10.1. Cell Therapies Forecast Methodology Overview
10.2. Pricing of Cell Therapies
10.3. Pipeline Launch Assumptions
10.4. Abbreviations
10.5. Methodology
10.6. About the Authors

11. Contact the Publisher

A selection of companies mentioned in this report includes

• BMS
• Autolus Therapeutics
• Sian Wuhan Medical Technology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/n47ew7

Source: GlobalData

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/chronic-lymphocytic-leukemia-cll-global-market-report-2023-featuring-bms-autolus-therapeutics--sian-wuhan-medical-technology-301749869.html

SOURCE Research and Markets

FAQ

What is the forecast for the Chronic Lymphocytic Leukemia (CLL) market through 2031?

The CLL cell therapy market is projected to reach $2 billion annually, with total market sales reaching $20.8 billion across 15 major markets.

What role does Autolus Therapeutics play in the CLL market?

Autolus Therapeutics is identified as a key player in the CLL market, particularly in the development of CAR-T therapies, which are part of the promising clinical pipeline.

What are the main challenges for CAR-T therapies in treating CLL?

The main challenges include manufacturing difficulties and the requirement for high safety profiles due to the low-grade nature of CLL.

How many markets does the CLL report analyze for pipeline therapies?

The report analyzes therapies across 15 major markets.

What is the significance of the report's time frame from 2021 to 2031 for CLL?

This time frame provides insights into the expected growth, trends, and future developments within the CLL market over the next decade.